通过Meta分析来评价雌激素受体β表达与结直肠癌临床病理特征及预后的关系，为雌激素受体β在结直肠癌诊断和治疗中的作用提供循证医学证据。

检索中国知网、万方、Cochrane Library、PubMed、SpringerLink、EBSCO、MEDLINE等数据库，检索建库开始至2019年12月所有研究雌激素受体β与结直肠癌的文献，提取相关临床资料和数据，根据纳入和排除标准，并根据Cochrane文献质量评估手册评估文献质量，最后采用RevMan 5.3进行Meta分析。

最终8篇文献2 149例患者纳入分析。雌激素受体β表达阳性患者预后更好，差异有统计学意义（HR=0.74，95% CI：0.63~0.86，P=0.000 1）。雌激素受体β表达与肿瘤的浸润程度有关，差异有统计学意义（OR=1.44，95% CI：1.15~1.80，P=0.002），而与性别（OR=1.17，95% CI：0.97~1.40，P=0.10）、肿瘤的分化程度（OR=0.96，95% CI：0.78~1.20，P=0.74）、淋巴结转移（OR=0.90，95% CI：0.74~1.11，P=0.33）、远处转移（OR=0.91，95% CI：0.67~1.23，P=0.55）等无关，差异无统计学意义。

雌激素受体β是结直肠癌的独立预后因子，在结直肠癌预后评估和治疗靶点方面具有重要作用。

To evaluate the relationship between estrogen receptor (ER) β expression and the clinicopathological characteristics and prognosis of colorectal cancer by Meta-analysis, and establish the evidence-based role of ER β in the diagnosis and treatment of colorectal cancer.

All the literature investigating ER β and colorectal cancer published in CNKI, Wangfang data, Cochrane Library, PubMed, SpringerLink, EBSCO, MEDLINE and other databases starting from the databases establishment to November 2019 were retrived. The relevant clinical data were extracted, and the literature quality was evaluated according to the Cochrane literature quality assessment manual. Meta analysis was conducted using Revman 5.3.

A total of 8 articles with 2 149 patients were included. The prognosis of patients with positive ER β expression was better (HR=0.74, 95% CI: 0.63-0.86, P=0.000 1). The expression of ER β was correlated with tumor invasion (OR=1.44, 95% CI: 1.15-1.80, P=0.002), while were not related to gender OR=1.17, 95% CI: 0.97-1.40, P=0.10), tumor differentiation (OR=0.96, 95% CI:0.78-1.20, P=0.74), lymph node metastasis (OR=0.90, 95% CI: 0.74-1.11, P=0.33), distant metastasis (OR=0.91, 95% CI: 0.67-1.23, P=0.55), the difference were not statistically significant.

ER βis an independent prognostic factor for colorectal cancer, and plays an important role in the prognosis prediction and therapeutic target for colorectal cancer.